Literature DB >> 29624511

Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.

Tsuyoshi Konishi1,2, Yoshifumi Shimada1,3, Lik Hang Lee4, Marcela S Cavalcanti4, Meier Hsu5, Jesse Joshua Smith1, Garrett M Nash1, Larissa K Temple1, José G Guillem1, Philip B Paty1, Julio Garcia-Aguilar1, Efsevia Vakiani4, Mithat Gonen5, Jinru Shia4, Martin R Weiser1.   

Abstract

This study aimed to compare common histologic markers at the invasive front of colon adenocarcinoma in terms of prognostic accuracy and interobserver agreement. Consecutive patients who underwent curative resection for stages I to III colon adenocarcinoma at a single institution in 2007 to 2014 were identified. Poorly differentiated clusters (PDCs), tumor budding, perineural invasion, desmoplastic reaction, and Crohn-like lymphoid reaction at the invasive front, as well as the World Health Organization (WHO) grade of the entire tumor, were analyzed. Prognostic accuracies for recurrence-free survival (RFS) were compared, and interobserver agreement among 3 pathologists was assessed. The study cohort consisted of 851 patients. Although all the histologic markers except WHO grade were significantly associated with RFS (PDCs, tumor budding, perineural invasion, and desmoplastic reaction: P<0.001; Crohn-like lymphoid reaction: P=0.021), PDCs (grade 1 [G1]: n=581; G2: n=145; G3: n=125) showed the largest separation of 3-year RFS in the full cohort (G1: 94.1%; G3: 63.7%; hazard ratio [HR], 6.39; 95% confidence interval [CI], 4.11-9.95; P<0.001), stage II patients (G1: 94.0%; G3: 67.3%; HR, 4.15; 95% CI, 1.96-8.82; P<0.001), and stage III patients (G1: 89.0%; G3: 59.4%; HR, 4.50; 95% CI, 2.41-8.41; P<0.001). PDCs had the highest prognostic accuracy for RFS with the concordance probability estimate of 0.642, whereas WHO grade had the lowest. Interobserver agreement was the highest for PDCs, with a weighted kappa of 0.824. The risk of recurrence over time peaked earlier for worse PDCs grade. Our findings indicate that PDCs are the best invasive-front histologic marker in terms of prognostic accuracy and interobserver agreement. PDCs may replace WHO grade as a prognostic indicator.

Entities:  

Mesh:

Year:  2018        PMID: 29624511      PMCID: PMC5943141          DOI: 10.1097/PAS.0000000000001059

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Hazard function estimators: a simulation study.

Authors:  K R Hess; D M Serachitopol; B W Brown
Journal:  Stat Med       Date:  1999-11-30       Impact factor: 2.373

Review 2.  Tumor-host interactions: a far-reaching relationship.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 3.  Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue.

Authors:  George S Karagiannis; Theofilos Poutahidis; Susan E Erdman; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Cancer Res       Date:  2012-09-28       Impact factor: 5.852

4.  Hazard rate estimation under random censoring with varying kernels and bandwidths.

Authors:  H G Müller; J L Wang
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

5.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.

Authors:  Laura S Rozek; Stephanie L Schmit; Joel K Greenson; Lynn P Tomsho; Hedy S Rennert; Gad Rennert; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2016-05-12       Impact factor: 13.506

6.  A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer.

Authors:  Simone Spaderna; Otto Schmalhofer; Falk Hlubek; Geert Berx; Andreas Eger; Susanne Merkel; Andreas Jung; Thomas Kirchner; Thomas Brabletz
Journal:  Gastroenterology       Date:  2006-09       Impact factor: 22.682

Review 7.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

Authors:  C C Compton; L P Fielding; L J Burgart; B Conley; H S Cooper; S R Hamilton; M E Hammond; D E Henson; R V Hutter; R B Nagle; M L Nielsen; D J Sargent; C R Taylor; M Welton; C Willett
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

8.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

Authors:  A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

9.  Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

Authors:  Jeffrey A Meyerhardt; Pamela B Mangu; Patrick J Flynn; Larissa Korde; Charles L Loprinzi; Bruce D Minsky; Nicholas J Petrelli; Kim Ryan; Deborah H Schrag; Sandra L Wong; Al B Benson
Journal:  J Clin Oncol       Date:  2013-11-12       Impact factor: 44.544

10.  Clinical Significance of Extramural Tumor Deposits in the Lateral Pelvic Lymph Node Area in Low Rectal Cancer: A Retrospective Study at Two Institutions.

Authors:  Ryoma Yagi; Yoshifumi Shimada; Hitoshi Kameyama; Yosuke Tajima; Takuma Okamura; Jun Sakata; Takashi Kobayashi; Shin-Ichi Kosugi; Toshifumi Wakai; Hitoshi Nogami; Satoshi Maruyama; Yasumasa Takii; Takashi Kawasaki; Kei-Ichi Honma
Journal:  Ann Surg Oncol       Date:  2016-07-08       Impact factor: 5.344

View more
  21 in total

1.  The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer.

Authors:  Serena Ammendola; Giulia Turri; Irene Marconi; Giulia Burato; Sara Pecori; Anna Tomezzoli; Cristian Conti; Corrado Pedrazzani; Valeria Barresi
Journal:  Virchows Arch       Date:  2020-06-23       Impact factor: 4.064

2.  Prognostic Significance of Lacunarity in Preoperative Biopsy of Colorectal Cancer.

Authors:  Gorana Aralica; Martina Šarec Ivelj; Arijana Pačić; Josip Baković; Marija Milković Periša; Anteja Krištić; Paško Konjevoda
Journal:  Pathol Oncol Res       Date:  2020-07-02       Impact factor: 3.201

Review 3.  Pathological assessment of endoscopic resections of the gastrointestinal tract: a comprehensive clinicopathologic review.

Authors:  M Priyanthi Kumarasinghe; Michael J Bourke; Ian Brown; Peter V Draganov; Duncan McLeod; Catherine Streutker; Spiro Raftopoulos; Tetsuo Ushiku; Gregory Y Lauwers
Journal:  Mod Pathol       Date:  2020-01-06       Impact factor: 7.842

4.  Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer.

Authors:  Yoshifumi Shimada; Shujiro Okuda; Yu Watanabe; Yosuke Tajima; Masayuki Nagahashi; Hiroshi Ichikawa; Masato Nakano; Jun Sakata; Yasumasa Takii; Takashi Kawasaki; Kei-Ichi Homma; Tomohiro Kamori; Eiji Oki; Yiwei Ling; Shiho Takeuchi; Toshifumi Wakai
Journal:  J Gastroenterol       Date:  2021-04-28       Impact factor: 7.527

5.  Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer.

Authors:  Martin R Weiser; Meier Hsu; Philip S Bauer; William C Chapman; Iván A González; Deyali Chatterjee; Deepak Lingam; Matthew G Mutch; Ajaratu Keshinro; Jinru Shia; Efsevia Vakiani; Tsuyoshi Konishi; Yoshifumi Shimada; Zsofia Stadler; Neil H Segal; Andrea Cercek; Leonard Saltz; Rona Yaeger; Anna Varghese; Maria Widmar; Iris H Wei; Emmanouil P Pappou; J Joshua Smith; Garrett Nash; Philip Paty; Julio Garcia-Aguilar; Mithat Gonen
Journal:  J Clin Oncol       Date:  2021-01-13       Impact factor: 44.544

6.  Deep Learning With Sampling in Colon Cancer Histology.

Authors:  Mary Shapcott; Katherine J Hewitt; Nasir Rajpoot
Journal:  Front Bioeng Biotechnol       Date:  2019-03-27

7.  SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer.

Authors:  Hidehito Oyanagi; Yoshifumi Shimada; Masayuki Nagahashi; Hiroshi Ichikawa; Yosuke Tajima; Kaoru Abe; Masato Nakano; Hitoshi Kameyama; Yasumasa Takii; Takashi Kawasaki; Kei-Ichi Homma; Yiwei Ling; Shujiro Okuda; Kazuaki Takabe; Toshifumi Wakai
Journal:  Histopathology       Date:  2019-04-01       Impact factor: 5.087

Review 8.  Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer.

Authors:  I A González; P S Bauer; J Liu; D Chatterjee
Journal:  Histopathology       Date:  2020-09-14       Impact factor: 5.087

Review 9.  Lateral lymph node dissection for low rectal cancer: Is it necessary?

Authors:  Niki Christou; Jeremy Meyer; Christian Toso; Frédéric Ris; Nicolas Christian Buchs
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

10.  Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).

Authors:  Hideki Ueno; Megumi Ishiguro; Eiji Nakatani; Toshiaki Ishikawa; Hiroyuki Uetake; Shigeyuki Matsui; Satoshi Teramukai; Kenta Murotani; Yoichi Ajioka; Hideyuki Shimazaki; Atsuyuki Maeda; Kunio Takuma; Takefumi Yoshida; Takeshi Kambara; Keiji Matsuda; Akinori Takagane; Naohiro Tomita; Kenichi Sugihara
Journal:  Am J Surg Pathol       Date:  2020-12       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.